open access

Vol 51, No 2 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-06-01
Submitted: 2019-10-22
Get Citation

Multiparameter flow cytometry for assessment of minimal residual disease in patients with myelodysplastic syndromes treated with allogeneic stem cell transplantation

Katarzyna Wiśniewska-Piąty, Joanna Dziaczkowska-Suszek, Agata Wieczorkiewicz-Kabut, Karolina Chromik, Anna Koclęga, Krzysztof Woźniczka, Iwona Grygoruk-Wiśniowska, Dariusz Kata, Patrycja Zielińska, Grzegorz Helbig
DOI: 10.2478/ahp-2020-0017
·
Acta Haematol Pol 2020;51(2):88-94.

open access

Vol 51, No 2 (2020)
ORIGINAL RESEARCH ARTICLE
Published online: 2020-06-01
Submitted: 2019-10-22

Abstract

Background

Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal myeloid neoplasms. Allogeneic stem cell transplantation (allo-SCT) remains the curative method for MDS treatment. Little is known about the monitoring of minimal residual disease (MRD) in patients with MDS after allo-SCT.

Aim

We aimed to evaluate the significance of leukemia-associated immunophenotypes (LAIPs) identified in acute myeloid leukemia (AML) for MRD monitoring in patients with MDS after allo-SCT.

Material and methods

Seven males and 4 females with a median age of 55 years were included. The diagnosis of MDS was established according to 2016 World Health Organization (WHO) criteria. The significance of eight LAIPs in bone marrow samples using multiparameter flow cytometry (MFC) was evaluated for MRD.

Results

Eight patients were positive for several LAIPs before allo-SCT. The identified LAIPs included the presence of aberrant lymphoid antigens on myeloblasts and lack of CD33 expression on myeloblasts. All studied MDS patients were negative for LAIPs at Day +30 after the procedure. This was followed by full-donor chimerism in all cases. The Ogata score after allo-SCT decreased in all patients in whom it was indicative for MDS before allo-SCT.

Conclusions

MFC could be useful in monitoring MRD in MDS patients after allo-SCT. Further studies in this field are needed.

Abstract

Background

Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal myeloid neoplasms. Allogeneic stem cell transplantation (allo-SCT) remains the curative method for MDS treatment. Little is known about the monitoring of minimal residual disease (MRD) in patients with MDS after allo-SCT.

Aim

We aimed to evaluate the significance of leukemia-associated immunophenotypes (LAIPs) identified in acute myeloid leukemia (AML) for MRD monitoring in patients with MDS after allo-SCT.

Material and methods

Seven males and 4 females with a median age of 55 years were included. The diagnosis of MDS was established according to 2016 World Health Organization (WHO) criteria. The significance of eight LAIPs in bone marrow samples using multiparameter flow cytometry (MFC) was evaluated for MRD.

Results

Eight patients were positive for several LAIPs before allo-SCT. The identified LAIPs included the presence of aberrant lymphoid antigens on myeloblasts and lack of CD33 expression on myeloblasts. All studied MDS patients were negative for LAIPs at Day +30 after the procedure. This was followed by full-donor chimerism in all cases. The Ogata score after allo-SCT decreased in all patients in whom it was indicative for MDS before allo-SCT.

Conclusions

MFC could be useful in monitoring MRD in MDS patients after allo-SCT. Further studies in this field are needed.

Get Citation

Keywords

myelodysplastic syndrome; multiparameter flow cytometry; allogeneic stem cell transplantation; leukemia-associated phenotype; minimal residual disease

About this article
Title

Multiparameter flow cytometry for assessment of minimal residual disease in patients with myelodysplastic syndromes treated with allogeneic stem cell transplantation

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 2 (2020)

Pages

88-94

Published online

2020-06-01

DOI

10.2478/ahp-2020-0017

Bibliographic record

Acta Haematol Pol 2020;51(2):88-94.

Keywords

myelodysplastic syndrome
multiparameter flow cytometry
allogeneic stem cell transplantation
leukemia-associated phenotype
minimal residual disease

Authors

Katarzyna Wiśniewska-Piąty
Joanna Dziaczkowska-Suszek
Agata Wieczorkiewicz-Kabut
Karolina Chromik
Anna Koclęga
Krzysztof Woźniczka
Iwona Grygoruk-Wiśniowska
Dariusz Kata
Patrycja Zielińska
Grzegorz Helbig

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl